A review on benefits of mass spectrometry for the small molecule drug discovery

The drug discovery is a very much time consuming as well as costly procedure. The Mass Spectrometry (MS) technology offers the aptitude for characterization, identification, as well as quantification of a target entity in a complex matrix and has settled into a leading analytical tool in the field of medicinal chemistry and drug discovery. However, by using specific MS-based techniques including personalized sample design, coupling to the gas and liquid chromatography and various ionization techniques, both qualitative as well as quantitative analysis of small molecular drug particles can be obtained. The current review describes MS strategies which are used to enhance and accelerate drug identification besides degradation linked impurities in active pharmaceutical ingredients (API) or articulated products. The level of protein expression is often termed as proteomics research. With use of MS technology, we can learn more reliable as well as dynamic ways of protein analysis.   Key words: MS, drug discovery, active pharmaceutical ingredients (API), spectroscopy.

[1]  Mir Sajjad Hussain Talpur,et al.  Role of selenium on oxidative stress and male reproductive system , 2017 .

[2]  Ronald A Miller,et al.  Mass spectrometry-based biomarkers in drug development. , 2014, Advances in experimental medicine and biology.

[3]  Christoph H. Borchers,et al.  Mass spectrometry based biomarker discovery, verification, and validation — Quality assurance and control of protein biomarker assays , 2014, Molecular oncology.

[4]  N. Kitteringham,et al.  Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  A. Rufer.  Drug discovery for enzymes. , 2021, Drug discovery today.

[6]  Yiyu Cheng,et al.  An ultra-robust fingerprinting method for quality assessment of traditional Chinese medicine using multiple reaction monitoring mass spectrometry , 2020, Journal of pharmaceutical analysis.

[7]  O. Chahrour,et al.  Development and validation of an ICP‐MS method for the determination of elemental impurities in TP‐6076 active pharmaceutical ingredient (API) according to USP <232>/<233> , 2017, Journal of pharmaceutical and biomedical analysis.

[8]  Mir Sajjad Hussain Talpur,et al.  A Novel Concept for Nano-Selenium Supplementation to Fight against COVID-19 , 2021, International Journal of Clinical and Experimental Medicine Research.

[9]  R. Szostak,et al.  Quantitative Determination of Vitamins A and E in Ointments Using Raman Spectroscopy , 2020, Processes.

[10]  I. Amster,et al.  Developments in Mass Spectrometry for Glycosaminoglycan Analysis: A Review , 2020, Molecular & cellular proteomics : MCP.

[11]  S. Carr,et al.  Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry , 2013, Nature Methods.

[12]  D. Russell,et al.  THE IMS PARADOX: A PERSPECTIVE ON STRUCTURAL ION MOBILITY-MASS SPECTROMETRY. , 2020, Mass spectrometry reviews.

[13]  R. Phadke,et al.  Drug Impurity profiling an emerging task to Pharmaceutical Industries now days - A Review , 2019, American Journal of PharmTech Research.

[14]  Ulrik H. Mistarz,et al.  Applications of Mass Spectrometry in Drug Development Science , 2016 .

[15]  K. Weitzel.  Bond-dissociation energies of cations--pushing the limits to quantum state resolution. , 2011, Mass spectrometry reviews.

[16]  A. Nordon,et al.  Process NMR spectrometry. , 2001, The Analyst.

[17]  Costel C. Darie,et al.  Identification of Posttranslational Modifications (PTMs) of Proteins by Mass Spectrometry. , 2019, Advances in experimental medicine and biology.

[18]  Z. Rehman,et al.  Research progress on the role of melatonin and its receptors in animal reproduction: A comprehensive review , 2018, Reproduction in domestic animals = Zuchthygiene.

[19]  R. Bauer,et al.  Natural products in drug discovery: advances and opportunities , 2021, Nature reviews. Drug discovery.

[20]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[21]  P. Oefner,et al.  Denaturing high‐performance liquid chromatography: A review , 2001, Human mutation.

[22]  G. Mitra.  Emerging Role of Mass Spectrometry‐Based Structural Proteomics in Elucidating Intrinsic Disorder in Proteins , 2020, Proteomics.

[23]  Xi-wu Zhang,et al.  Mass spectrometry-based metabolomics in health and medical science: a systematic review , 2020, RSC advances.

[24]  Davy Guillarme,et al.  Adding a new separation dimension to MS and LC-MS: What is the utility of ion mobility spectrometry? , 2018, Journal of separation science.

[25]  Ashley R. Johnson,et al.  Drug eluting implants in pharmaceutical development and clinical practice , 2020, Expert opinion on drug delivery.

[26]  Lennart Martens,et al.  Simple Peptide Quantification Approach for MS-Based Proteomics Quality Control , 2020, ACS omega.

[27]  Z. Shahrokh,et al.  Mass Spectrometry Innovations in Drug Discovery and Development , 2001, Pharmaceutical Research.

[28]  Longhai Jian,et al.  Screening for illegal addition of glucocorticoids in adulterated cosmetic products using ultra-performance liquid chromatography/tandem mass spectrometry with precursor ion scanning. , 2020, Rapid communications in mass spectrometry : RCM.

[29]  K. Ito,et al.  Impact of post-translational modifications of proteins on the inflammatory process. , 2007, Biochemical Society transactions.